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Abstract The objective of this study was to develop and
validate a time-dependent logistic regression model for
prediction of locoregional recurrence (LRR) of breast can-
cer and a web-based nomogram for clinical decision sup-
port. Women first diagnosed with early breast cancer
between 2003 and 2006 in all Dutch hospitals were selected
from the Netherlands Cancer Registry (n = 37,230). In the
first 5 years following primary breast cancer treatment, 950
(2.6 %) patients developed a LRR as first event. Risk fac-
tors were determined using logistic regression and the risks
were calculated per year, conditional on not being diag-
nosed with recurrence in the previous year. Discrimination
and calibration were assessed. Bootstrapping was used for
internal validation. Data on primary tumours diagnosed
between 2007 and 2008 in 43 Dutch hospitals were used for
external validation of the performance of the nomogram
(n = 12,308). The final model included the variables grade,
size, multifocality, and nodal involvement of the primary
tumour, and whether patients were treated with radio-,
chemo- or hormone therapy. The index cohort showed an
area under the ROC curve of 0.84, 0.77, 0.70, 0.73 and 0.62,
respectively, per subsequent year after primary treatment.
Model predictions were well calibrated. Estimates in the
validation cohort did not differ significantly from the index
cohort. The results were incorporated in a web-based
nomogram (http://www.utwente.nl/mira/influence). This
validated nomogram can be used as an instrument to iden-
tify patients with a low or high risk of LRR who might
benefit from a less or more intensive follow-up after breast
cancer and to aid clinical decision making for personalised
follow-up.
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Background
A locoregional recurrence (LRR) has a high risk of distant
metastasis, and thus confers a poor prognosis [1]. LRRs are
defined as the reappearance of breast cancer on the same
site as the primary tumour, in the chest wall or ipsilateral,
infraclavicular, supraclavicular or parasternal lymph nodes
after curative treatment [2]. Factors that influence the risk
of recurrence include tumour size, age, vascular invasion,
multifocality, histological grade, hormone receptor status
and treatment of the primary tumour [3–13]. Regular fol-
low-up is aimed at detecting LRRs in an early stage to
improve survival [14]. In the Netherlands, patients are
followed clinically for at least 5 years after their treatment.
Still, most of the recurrences are detected by the women
themselves in between follow-up visits and some are
detected after the 5 years of clinical follow-up [15, 16]. In
a Dutch multicentre study, Geurts et al. [14] found that
only 34 % of the LRRs were detected asymptomatically
during routine visits. Due to the increase in survival, the
burden of follow-up on health care is rising. Even though
the risk factors are known, follow-up is the same for all
patients and not dependent on the personal risk of the
individual breast cancer patient. Since 2012, the national
guideline of the Netherlands recommends an individualised
follow-up by shared decision making, but does not provide
recommendations on how to effectuate it. To achieve this,
good insight into time-dependent individual LRR risk is
necessary.
Statistical models that are used for predicting the out-
comes of patients are called prognostic models. Many
prognostic models appear to be adequate at the population
level. However, their use to predict risks on the level of the
individual patient is questionable. Patients and clinicians
need accurate risks on the individual patient level to reach
more informed and uniform decision making. Challenges
are incomplete knowledge on causality and the existence of
various risk factors with only a small effect [17, 18]. For
the prediction of breast cancer, the first model was devel-
oped by Gail et al. [19]. This model, as well as other well-
known models (e.g. BRCAPRO, BOADICEA [20], [21]) is
aimed at predicting the general risk of primary breast
cancer. To get towards personalised follow-up, models
predicting LRRs are required. In this paper, logistic
regression is used to calculate the risks. Not only the single
risk estimated for the overall follow-up period of 5 years,
but also the annual time-dependent risk. To facilitate
uptake in clinical practice, ease of use and accessibility are
crucial. This can be achieved by using a nomogram: a
graphical representation of the underlying model. Our aim
is to develop and validate a time-dependent logistic
regression model and nomogram suitable for the annual
risk prediction of LRRs in individual breast cancer patients.
Knowing this individual risk could facilitate the decision
on a personalised follow-up plan.
Patients and methods
Study population
Patients were selected from the Netherlands Cancer Reg-
istry (NCR), a nationwide population-based registry, which
records all newly diagnosed tumours since 1989. The
information on patient, tumour and treatment characteris-
tics, as well as data concerning recurrences within the first
5 years following primary breast cancer were recorded
from the patient files by specially trained registration
clerks.
Women diagnosed with primary invasive breast cancer
between 2003 and 2006 without distant metastasis, previ-
ous, or synchronous tumours (diagnosed within 3 months
after the first tumour [22]), treated with curative intent and
without neo-adjuvant systemic treatment were selected
from the registry (n = 37,230). Curative intent was defined
as surgical removal of the primary tumour without
macroscopic residual disease. Adjuvant treatment should
have been received in case of microscopic residue. In the
first 5 years following primary breast cancer treatment, 950
(2.6 %) of the selected patients developed a LRR as a first
event. For external validation, data were used of a cohort of
12,308 patients from a selection of Dutch hospitals (43 out
of 91) that developed their primary breast cancer between
the years 2007 and 2008. Of these patients, 275 (2.2 %)
were diagnosed with a LRR.
Although second primary breast cancers (any epithelial
breast cancer with or without lymph node metastasis in the
contralateral breast [2]) are also of interest with regard to
follow-up care, they are not included in the model. Second
primary tumours are a different entity from the primary
tumour, and are hard to predict based on the available
clinical variables [23–25]. Patients with a known genetic
predisposition (estimates vary between 3 to around 7 %
[26–28]) are not part of the regular follow-up. Unless they
underwent a double mastectomy, they undergo a separate,
more intensive follow-up.
Model development
Variables were selected based on literature and availability
of the data. As the effect of age on LRR risk is nonlinear, it
was discretized into four groups (\50, 50–59,
60–69, C70). The patient, tumour and treatment charac-
teristics shown in Table 1 were assessed for their influence
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on recurrence risk using multivariable binary logistic
regression analysis. By means of backward elimination, we
deleted variables from the initial model until only variables
with a P value of\0.157 (Akaike information criterion)
were maintained in the model. A last check was performed
by adding and removing the variables one by one. Firstly, a
prediction model for the 5-year LRR risk was developed.
Secondly, risks were determined per year conditional on
not being diagnosed with recurrence in the previous
year(s). Interaction was tested by adding interaction terms
to the model. A correlation matrix was composed to assess
possible correlation between the variables. Variables with a
high correlation coefficient ([0.7 or\-0.7) were exclu-
ded. With a ratio of around 100:1, there were enough
Table 1 Patient and tumour characteristics
Index cohort Validation
cohort
P Index cohort Validation
cohort
P
(2003–2006) (2007–2008) (2003–2006) (2007–2008)
n % n % n % n %
Total 37,278 12,318 PR status 0.004
Age category \0.001 Negative 9580 33.7 3806 32.2
\50 9779 26.2 3006 24.4 Positive 18,877 66.3 8018 67.8
50–59 10,601 28.4 3353 27.2 Unknown 8821 494
60–69 8421 22.6 3101 25.2 Her2-Neu status 0.017
C70 8477 22.7 2858 23.2 Negative 13,832 85.2 10,238 86.2
Histologic type 0.300 Positive 2405 14.8 1639 13.8
Ductal 29,582 79.4 9795 79.5 Unknown 21,041 441
Lobular 4000 10.7 1271 10.3 Number of surgeries 0.383
Mixed 1552 4.2 551 4.5 1 33,136 88.9 10,926 88.7
Other 2144 5.8 701 5.7 2 3909 10.5 1301 10.6
Grade \0.001 C3 233 0.6 91 0.7
I 7628 22.0 2907 24.5 Type of surgery \0.001
II 15,595 44.9 5253 44.3 Breast conserving 21,049 56.5 7215 58.6
III 11,479 33.1 3700 31.2 Non-breast conserving 16,229 43.5 5103 41.4
Unknown 2576 458 Time from indicence to last OK 0.720
Tumour size \0.001
B2 cm 22,611 61.2 7796 63.7 \30 days 27,579 74.0 9098 73.9
2-5 cm 13,243 35.8 4152 33.9 30–60 days 8205 22.0 2742 22.3
[5 cm 1094 3.0 283 2.3 [60 days 1494 4.0 478 3.9
Unknown 330 87 Axillary lymph node dissection \0.001
Multifocal 0.257
No 23,237 84.8 10,275 84.3 No 18,397 49.4 7315 59.4
Yes 4168 15.2 1907 15.7 Yes 18,881 50.6 5003 40.6
Unknown 9873 136 Chemotherapy \0.001
Lymph node status \0.001 No 23,886 64.1 7583 61.6
Negative 22,516 61.3 7809 64.0 Yes 13,392 35.9 4735 38.4
1–3 positive 10,093 27.5 3189 26.2 Radiotherapy 0.001
[3 positive 4119 11.2 1196 9.8 No 12,783 34.3 4026 32.7
Unknown 550 124 Yes 24,495 65.7 8292 67.3
ER status 0.001 Hormone therapy \0.001
Negative 5417 18.8 2113 17.3 No 21,696 58.2 6563 53.3
Positive 23,433 81.2 10,066 82.7 Yes 15,582 41.8 5755 46.7
Unknown 8428 139
LRR locoregional recurrence, ER oestrogen receptor, PR progesterone receptor, Her2-Neu human epidermal growth factor receptor 2
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events for the included variables in the model. Based on
simulation studies, it was determined that the ratio should
be at least 10:1 [29].
The percentage of missing values of the included vari-
ables ranged between 0 and 24 % (PR status). ER and PR
status were not registered by the NCR on a regular basis in
2003 and 2004. The variables of the prediction model with
missing values were multiple imputed using a chained
equation approach [30–32]. Calculations were performed
with the MICE package of R. It was assumed that missing
values occurred randomly, which validates the use of
imputation. A comparison with the complete case analysis
was made, as well as an assessment of the convergence.
The analyses were repeated on the imputed data and pooled
by using Rubin’s rules.
Validation
Prognostic validity or discrimination refers to the capabil-
ity to discern between high and low-risk patients [33]. It
was measured by the Harrell c-statistic from area under the
receiver operating characteristic (ROC). A c-statistic of 1.0
indicates perfect predictive ability, whereas 0.5 represents
no predictive discrimination. Calibration, whether the
predicted probabilities accord with the observed ones, was
evaluated by the Hosmer–Lemeshow goodness-of-fit test in
deciles. A P value above 0.05 (indicating no significant
difference between the model and the data) is generally
considered as a satisfactory goodness-of-fit. Plotting the
difference between the observed and predicted probabili-
ties was used for graphical assessment of the calibration.
To see if the model can effectively differentiate between
women who will develop a LRR and women who will not,
the model was validated. For internal validation, boot-
strapping (n = 1000) was used because it provides stable
estimates [34]. If the shrinkage factor from the validation is
over 0.85, it is considered satisfactory [35]. External vali-
dation was performed by regression analyses on the vali-
dation cohort. Areas under the ROC curves were compared
using the jackknife method proposed by DeLong et al. [36].
A P value\ 0.05 was considered statistically significant.
Analyses were performed using STATA version 13 and R
3.1.1 software (http://www.r-project.org). The nomogram
was developed using HTML and jQuery (JavaScript).
Results
After backward elimination, the model included the vari-
ables grade, size, multifocality and nodal involvement of
the primary tumour, type of surgery, and whether patients
were treated with radio-, chemo- or hormone therapy
(Table 2). Assessment of the correlations revealed a high
correlation between type of surgery and use of radiotherapy
(correlation coefficient -0.8). Since radiotherapy showed a
higher influence on the risk, type of surgery was omitted
from the model. Due to high correlation between the
oestrogen (ER) and progesterone (PR) receptor status, they
were combined into one variable (ER/PR negative versus
other). Inclusion of interaction terms did not improve the
model. The patients in the index and validation cohort had
small differences in the included variables age, grade, size,
lymph node status, hormone status and treatments (all
\3 % per category, Table 1). Healthy convergence was
achieved with the multiple imputations.
Validation
Table 3 details the discrimination and calibration proper-
ties of the prediction model. The probability measure of the
predictive ability given as the c-statistic was 0.71 for the
5-year risk of LRR (95 % confidence interval [CI]
0.69–0.73); indicating good discriminating ability. Per
subsequent year after primary treatment, the index group
showed an area under the ROC curve of 0.84, 0.76, 0.70,
0.73 and 0.65, respectively. The predictions were well
calibrated, as can be seen in the Hosmer–Lemeshow
goodness-of-fit test (Fig. 1). For the deciles, the average
expected to observed ratio was 1.05 and the P value 0.28,
indicating a high agreement between the predictions and
observations.
Internal validation in the index group with 1000 times
bootstrapping revealed a shrinkage factor of 0.98 for the
5-year risk estimates (Table 3). In the external validation,
all effects in the validation group were in the same direc-
tion, and the estimates in the validation group did not differ
significantly from the index group. Tumour size,
chemotherapy and hormone therapy had a slightly higher
influence in the validation cohort (Table 2). The compar-
ison between the ROC curves from the index and valida-
tion group can be found in Fig. 2.
The models based on the imputed data were embedded
in the nomogram which is available on http://www.
utwente.nl/mira/influence. Figure 3 provides a screenshot
of the nomogram which shows the time-dependent risk of a
theoretical patient aged between 50 and 59, with a T2M0N1,
grade II, hormone status negative primary tumour, who did
receive hormone therapy, but no radio- or chemotherapy.
Discussion
This study describes the development and validation of the
first-ever time-dependent logistic regression model for the
prediction of the annual risk of LRR of breast cancer,
developed based on data from 37,230 patients. The model
630 Breast Cancer Res Treat (2015) 152:627–636
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Table 2 Logistic regression estimates
Five year risk Conditional yearly risk
2003–2006 2007–2008 2003–2006
n = 37,230, 950 LRRs n = 12,308, 275 LRRs Year 1, 150 LRRs Year 2, 268 LRRs
OR 95 % CI P OR 95 % CI P OR 95 % CI P OR 95 % CI P
Age
\50 Ref. Ref. Ref. Ref.
50–59 0.62 0.49–0.78 \0.001 0.65 0.45–0.93 0.019 0.63 0.33–1.19 0.152 0.83 0.56–1.22 0.340
60–69 0.61 0.47–0.79 \0.001 0.60 0.41–0.89 0.011 0.54 0.26–1.13 0.103 0.64 0.40–1.03 0.065
C70 0.41 0.31–0.55 \0.001 0.55 0.36–0.85 0.007 0.65 0.31–1.36 0.251 0.40 0.23–0.71 0.002
Tumour size
B2 cm Ref. Ref. Ref. Ref.
2–5 cm 1.35 1.10–1.64 0.003 1.57 1.15–2.14 0.005 1.75 1.03–2.98 0.038 1.51 1.06–2.14 0.022
[5 cm 1.08 0.63–1.86 0.780 2.96 1.48–5.93 0.002 2.21 0.83–5.88 0.112 1.32 0.55–3.16 0.539
Nodal involvement
0 Ref. Ref. Ref. Ref.
1–3 1.64 1.32–2.04 \0.001 1.60 1.14–2.24 0.007 2.36 1.32–4.21 0.004 1.53 1.05–2.24 0.028
[3 2.90 2.14–3.94 \0.001 3.10 1.95–4.94 \0.001 8.49 4.31–16.73 \0.001 2.94 1.77–4.90 \0.001
Grade of differentiation
1 Ref. Ref. Ref. Ref.
2 1.92 1.45–2.54 \0.001 1.60 1.10–2.34 0.014 2.76 1.05–7.23 0.039 1.27 0.74–2.17 0.386
3 2.96 2.16–4.05 \0.001 2.38 1.51–3.72 \0.001 4.06 1.34–11.33 0.008 2.24 1.26–3.99 0.006
Hormone status
Other Ref. Ref. Ref. Ref.
ER & PR negative 1.41 1.08–1.84 0.011 1.44 0.96–2.16 0.076 1.82 0.953.49 0.069 2.57 1.58–4.17 \0.001
Multifocality
No Ref. Ref. Ref. Ref.
Yes 1.23 0.99–1.54 0.062 1.19 0.85–1.67 0.307 1.19 0.68–2.09 0.543 0.94 0.62–1.43 0.777
Radiotherapy
No Ref. Ref. Ref. Ref.
Yes 0.51 0.43-0.62 \0.001 0.50 0.38-0.66 \0.001 0.31 0.19-0.52 \0.001 0.36 0.26-0.50 \0.001
Chemotherapy
No Ref. Ref. Ref. Ref.
Yes 0.43 0.33–0.56 \0.001 0.34 0.23-0.52 \0.001 0.39 0.19–0.79 0.009 0.56 0.35–0.89 0.015
Hormone therapy
No Ref. Ref. Ref. Ref.
Yes 0.41 0.32-0.53 \0.001 0.35 0.24-0.51 \0.001 0.16 0.08-0.35 \0.001 0.57 0.35-0.92 0.020
Intercept
0.04 0.03–0.05 \0.001 0.04 0.03–0.07 \0.001 0.00 0.00–0.01 \0.001 0.01 0.01–0.02 \0.001
Conditional yearly risk
2003–2006
Year 3, 203 LRRs Year 4, 164 LRRs Year 5, 165 LRRs
OR 95 % CI P OR 95 % CI P OR 95 % CI P
Age
\50 Ref. Ref. Ref.
50–59 0.64 0.38–1.08 0.092 0.51 0.31–0.85 0.009 0.45 0.25–0.79 0.006
60–69 0.82 0.47–1.41 0.465 0.44 0.25-0.77 0.004 0.62 0.35–1.09 0.099
C70 0.59 0.31–1.11 0.101 0.30 0.16–0.56 \0.001 0.31 0.15–0.63 0.001
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takes into account the age of the patient, grade, size,
multifocality, and nodal involvement of the primary
tumour, and whether patients were treated with radio-,
chemo- or hormone therapy. The risk factors used in our
model are filtered from the population-based registry and
are readily available in (Dutch) clinical practice and for use
of the nomogram, without extra efforts or data gathering.
Validation displayed only a small overestimation of the
risk of developing a LRR (as could be expected with large
sample sizes [37]).
In a systematic review on primary breast cancer risk
prediction models, it was found that calibration of most
models was sufficient [38]. However, discriminatory
accuracy was considered poor to fair (c-statistic of
0.52–0.66) after internal validation. Reasons provided were
lack of knowledge on risk factors, the different subtypes of
breast cancer and discrepancies between risk factors across
populations [38]. In this study, both calibration and dis-
crimination (c-statistic of 0.71 after validation) were sat-
isfactory. The individual risk estimates do show
uncertainty, particularly in the later years. So risk estimates
still need to be interpreted with caution. With nodal
involvement being the highest risk factor (odds ratio (OR)
2.9 for[3 nodes compared to negative nodes for the 5 year
risk, up to OR 8.5 for the risk in the first year), the effects




Year 3, 203 LRRs Year 4, 164 LRRs Year 5, 165 LRRs
OR 95 % CI P OR 95 % CI P OR 95 % CI P
Tumour size
B2 cm Ref. Ref. Ref.
2–5 cm 1.20 0.79–1.84 0.393 1.65 1.04–2.64 0.035 0.79 0.47–1.32 0.364
[5 cm 0.36 0.05–2.65 0.314 0.51 0.07–3.85 0.510 0.79 0.18–3.42 0.750
Nodal involvement
0 Ref. Ref. Ref.
1–3 2.48 1.58–3.90 \0.001 1.10 0.63–1.92 0.732 0.98 0.55–1.73 0.942
[3 1.92 0.88–4.20 0.102 1.90 0.87–4.14 0.105 1.83 0.82–4.07 0.137
Grade of differentiation
1 Ref. Ref. Ref.
2 1.55 0.88–2.71 0.127 3.28 1.71–6.30 \0.001 1.89 1.05–3.40 0.034
3 2.41 1.27–4.57 0.007 4.95 2.33–10.49 \0.001 2.22 1.10–4.51 0.026
Hormone status
Other Ref. Ref. Ref.
ER & PR negative 1.16 0.65–2.07 0.625 0.78 0.41–1.47 0.443 0.63 0.28–1.41 0.261
Multifocality
No Ref. Ref. Ref.
Yes 1.56 0.99–2.47 0.054 2.18 1.38–3.45 0.001 0.68 0.35–1.30 0.244
Radiotherapy
No Ref. Ref. Ref.
Yes 0.58 0.39-0.86 0.008 0.85 0.55-1.30 0.454 0.75 0.47-1.19 0.220
Chemotherapy
No Ref. Ref. Ref.
Yes 0.52 0.29–0.92 0.025 0.26 0.14–0.49 \0.001 0.45 0.23–0.87 0.018
Hormone therapy
No Ref. Ref. Ref.
Yes 0.38 0.22-0.65 \0.001 0.32 0.18-0.57 \0.001 0.96 0.53-1.73 0.891
Intercept
0.01 0.00–0.01 \0.001 0.01 0.00–0.01 \0.001 0.01 0.00-0.02 \0.001
OR odds ratio, CI confidence interval, LRR locoregional recurrence, ER oestrogen receptor, PR progesterone receptor
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et al. [17] advocate that for prediction of individual risks,
the relative risk of factors should exceed ten to be a good
predictor of individual risk (even though this does not
warrant discriminatory accuracy). Subsequently, individual
predictions should be improved by decreasing the unex-
plained variation. Based on the conventional clinical risk
factors, this is not to be expected. Hence more research is
needed to discover new characteristics with discriminative
ability [18].
This study had a number of strengths including data on
many variables associated with risk of LRR and a large
sample size. Also, the sample size of the validation cohort
was appropriately large, as a minimum of 100 events and
hundred non-events was proposed by Vergouwe et al. [39]
for an external validation population. A correction for
possible subsequent recurrences was unfortunately not
feasible, while only first and synchronous recurrences are
registered in the NCR. Although information on other
known risk factors such as vascular invasion and breast
density was unavailable and could not be taken into
account, the nomogram can be updated to incorporate more
variables when they become available in clinical practice
and registries [40]. Of note, our analysis showed that Her2-
Neu and primary tumour morphology were not independent
predictors of LRR. These findings are in contrast to that of
previous studies [10, 41]. This could be due to the fact that
all Her2-Neu positive patients are treated with herceptin in
the Netherlands. Our nomogram was based on data of
almost all diagnosed early primary breast cancers between
2003 and 2006; thus, the results should be generalizable to
the Dutch population. Another strength is the presentation
of the conditional risk through time instead of only a 5-year
Table 3 Model validation
5 year risk Yearly risk
Index cohort 2003–2006 Validation cohort 2007–2008 2003–2006
Year 1 Year 2 Year 3 Year 4 Year 5
Discrimination
C-statistic 0.71 0.70 0.84 0.77 0.70 0.73 0.62
Calibration
LR test (P value) \0.001 \0.001 \0.001 \0.001 \0.001 \0.001 0.014
Goodness-of-fit testa (P value) 0.2817 0.0897 0.1455 0.1767 0.5504 0.5182 0.8685
Internal validation
Shrinkage factor 0.98 Na 0.95 0.96 0.88 0.88 0.65
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Fig. 2 ROC curves of the index (n = 37,230) and validation
(n = 12,308) cohort for 5-year LRR risks
Breast Cancer Res Treat (2015) 152:627–636 633
123
risk estimate, which enables the clinician to give a better
assessment of the risk over time for patients and adjust the
follow-up plan accordingly.
The difference in treatment between the index and val-
idation cohort can be attributed to changing guidelines over
time. If the risk is of LRR is high, it could be considered to
use adjuvant treatment. However, this is outside the scope
of this study, the model is targeted at patients who have
completed their treatment. The nomogram can be improved
with automatic updating: the new patients will cause
adjustments of the estimates, and new patients will weigh
more than the less recent ones to better tailor the model to
the current clinical practice.
User-friendly access through a nomogram is beneficial
for both patients and clinicians. Still, it remains important
that the users understand the correct interpretation.
Therefore, it is of great importance to present the estimates
with the corresponding CI [42]. Much used nomograms
like for example Adjuvant! Online (adjuvant treatment
decisions) [43], the nomograms from Memorial Sloan
Kettering Cancer Center (o.a. likelihood that breast cancer
has spread to sentinel lymph nodes) [44] or IBTR! (benefit
of adjuvant radiotherapy) [45] do not display these
intervals, which makes it hard to appreciate the certainty of
the risk estimates.
Current guidelines for follow-up after breast cancer
aimed at detecting LRRs at an early, asymptomatic stage
prescribe equal follow-up for every patient. This research
shows there is a great variability in the risk of LRR,
underlining the need for an individualised follow-up. With
simulation modelling, thresholds can be found for when to
assign the visits, so that using the yearly risk predictions,
individual follow-schedules can be developed. This will
lower the burden on both patients and care providers, as
well as health care resources.
Conclusion
This time-dependent logistic regression model for the
prediction of the annual risk of LRR of breast cancer
nomogram is simple to use and shows a good predictive
ability in the Dutch population. It can be used as an
instrument to identify patients with a high risk of LRR who
might benefit from a less or more intensive follow-up after
breast cancer and to aid clinical decision making.
Fig. 3 Print screen from the
nomogram, providing the time-
dependent risk of a fictional
patient
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